IP Library › Granted Patent US 7,317,089
Granted Patent B2
US 7,317,089 · App. 10/484,790 · Granted Jan 8, 2008

Antagonistic anti-hTNFSF13b human antibodies

Assignee: Eli Lilly and Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,317,089
App. No.
10/484,790
Granted
Jan 8, 2008
Kind
B2
Abstract

Human monoclonal antibodies that specifically bind to TNFSF13 b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13 b (e.g., K D =10 −8 M or less), a slow off rate for TNFSF13 b dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize TNFSF13 b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13 b activity in a human subject suffering from a disorder in which hTNFSF13 b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.

Claims (3)

1. An anti-hTNFSF13b human antibody, Fab fragment, Fab′ fragment, F(ab′)2 fragment, or single chain FV fragment comprising SEQ ID NO: 2 and SEQ ID NO: 10.

2. An anti-hTNFSF13b human antibody comprising SEQ ID NO: 17 and SEQ ID NO: 19.

3. An anti-hTNFSF13b human antibody comprising SEQ ID NO: 18 and SEQ ID NO: 19.

Continuity (1)
Related Publication 20050070694A1 · Mar 31, 2005